Moderna Inc. said it will reduce annual spending by about $1.5 billion by 2027 as the company continues to cut costs to ...

On a Thursday conference call with investors, Moderna CFO Jamey Mock outlined a roadmap for the mRNA specialist to lower its ...

Additional data required by the FDA are the latest evidence of what one analyst described as a “higher bar” for vaccines.

Founded in 1993, The Motley Fool is a financial services company dedicated to making the world smarter, happier, and richer.

MRNA reports mixed Q1 results. The company reiterates 2025 sales guidance but announces a cost-cutting initiative to reduce ...

Moderna (NASDAQ:MRNA) accelerates cost cuts, trimming 2026 GAAP operating expenses by up to $500 million as COVID-19 vaccine ...

Have you ever wondered about what became of COVID vaccine companies after the pandemic settled down? Find out in this article ...

Jefferies analysts said Moderna’s first quarter was “in line,” with a miss on revenue offset by a beat on earnings per share.

Here are eight possible indicators of how health secretary Robert F. Kennedy Jr. may handle U.S. vaccine policy in coming ...

COVID - 19: The Company reported $84 million in Spikevax® sales in the first quarter of 2025, which includes $29 million of U.S. sales and $55 million of international sales. As previously reported, ...

Moderna reiterated its full-year 2025 product sales forecast of $1.5 billion to $2.5 billion, with most expected in the ...

Comments over the weekend by FDA chief Martin Makary suggest the agency views Novavax’s updated COVID shot as a “new product” ...